Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Infante

Showing results (221-230 of 299) with videos related to

Pageof 30
Sort By:
Investigational New Drugs|November 27, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumorsJeffrey R Infante, Silvia Novello, Wen Wee Ma, et al.
Elife|March 16, 2016
Molecular shifts in limb identity underlie development of feathered feet in two domestic avian speciesEric T Domyan, Zev Kronenberg, Carlos R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumorsJeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
British Journal of Cancer|January 24, 2018
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
British Journal of Cancer|September 27, 2017
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
Developmental Biology|December 20, 2011
Somitogenesis in the anole lizard and alligator reveals evolutionary convergence and divergence in the amniote segmentation clockWalter L Eckalbar, Eris Lasku, Carlos R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Investigational New Drugs|September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatinJhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
Molecular Cancer Therapeutics|June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumorsHoward A Burris, Afshin Dowlati, Rebecca A Moss, et al.
Pageof 30

Showing results (221-230 of 299) with videos related to

Sort By:
Pageof 30
Investigational New Drugs|November 27, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumorsJeffrey R Infante, Silvia Novello, Wen Wee Ma, et al.
Elife|March 16, 2016
Molecular shifts in limb identity underlie development of feathered feet in two domestic avian speciesEric T Domyan, Zev Kronenberg, Carlos R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumorsJeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
British Journal of Cancer|January 24, 2018
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
British Journal of Cancer|September 27, 2017
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
Developmental Biology|December 20, 2011
Somitogenesis in the anole lizard and alligator reveals evolutionary convergence and divergence in the amniote segmentation clockWalter L Eckalbar, Eris Lasku, Carlos R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Investigational New Drugs|September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatinJhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
Molecular Cancer Therapeutics|June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumorsHoward A Burris, Afshin Dowlati, Rebecca A Moss, et al.
Pageof 30